A Study to Compare the Effect of Eprosartan versus Eprosartan Mesylate on Blood Pressure in Subjects with High Blood Presure

Registry ID

EUCTR2010-019155-22

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Abbott Healthcare Products B.V.

Start date

2012-04-17

Completion date

2013-04-30

Last update

2026-08-16

Conditions

• Essential Hypertension

Summary

To assess the therapeutic equivalence of eprosartan (a new formulation containing only the active moiety eprosartan) with eprosartan mesylate (currently marketed formulation) on sitting diastolic blood pressure (DBP) in ambulatory subjects with mild to moderate essential hypertension after 8 weeks of treatment (monotherapy).

Locations

• , , Germany
• , , UK

Related clinical trials

• Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
• Childhood-Onset Essential Hypertension Natural History Study
• Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
• Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
• To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
• Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）

View on source registry